BioNexus Gene Lab Corp. Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)
BioNexus Gene Lab Corp. (BGLC) reported Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) of -$7.20 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › and Others › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease · last filed 2026-08-14
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2026-06-30 was -$6.35K, a 124.04% decline year-over-year.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2026-03-31 was -$846.00, a 116.45% decline year-over-year.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2025-12-31 was $24.70K.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2025-09-30 was $1.29K.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2024 was $16.25K.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2023 was -$6.92K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 3 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 6 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 9 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 12 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$6.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$7.20K 10-Q · filed 2026-08-14 | $17.50K derived: sum of 3 quarters · filed 2026-08-14 | $18.79K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$846.00 10-Q · filed 2026-05-15 | $23.85K derived: sum of 2 quarters · filed 2026-08-14 | $25.14K derived: sum of 3 quarters · filed 2026-08-14 | $51.58K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $24.70K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | $25.99K derived: sum of 2 quarters · filed 2026-08-14 | $52.42K derived: sum of 3 quarters · filed 2026-08-14 | $57.56K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $1.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $27.73K derived: sum of 2 quarters · filed 2025-11-14 | $32.87K 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $26.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $31.58K 10-Q · filed 2025-08-18 | |||
| 2025-03-31 | $5.14K 10-Q · filed 2025-05-15 | ||||
| 2024-12-31 | $16.25K 10-K · filed 2026-04-14 | $16.26K 10-K · filed 2025-04-15 | |||
| 2023-12-31 | -$6.92K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |